Trials / Completed
CompletedNCT06089278
A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trials to Assess the Effectiveness, Safety and Pharmacokinetics of TQH2722 Injection in Patients With Chronic Sinusitis With or Without Nasal Polyps.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 300mg of TQH2722 injection | TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade. |
| DRUG | 600mg of TQH2722 injection | TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade. |
| DRUG | TQH2722 injection matching placebo | Placebo without active substance. |
Timeline
- Start date
- 2023-12-28
- Primary completion
- 2025-03-30
- Completion
- 2025-04-30
- First posted
- 2023-10-18
- Last updated
- 2025-07-14
Locations
36 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06089278. Inclusion in this directory is not an endorsement.